Antibacterial drug resistance is the process that bacteria use to tolerate and overcome the effects of antibiotic drugs. Resistance can arise through mutations or can be acquired from other bacteria through plasmids.

Market Analysis and Insights: Global and United States Antibacterial (Drug) Resistance Market
This report focuses on global and United States Antibacterial (Drug) Resistance market.
In 2020, the global Antibacterial (Drug) Resistance market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In United States the Antibacterial (Drug) Resistance market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Antibacterial (Drug) Resistance Scope and Market Size
Antibacterial (Drug) Resistance market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Antibacterial (Drug) Resistance market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For United States market, this report focuses on the Antibacterial (Drug) Resistance market size by players, by Type, and by Indication, for the period 2016-2027. The key players include the global and local players which play important roles in United States.

Segment by Type
Telavancin (Vibativ)
Ceftaroline Fosamil (Teflaro/ Zinforo)
Fidaxomicin (Dificid / Dificlir)
Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Dalbavancin (Dalvance/ Xydalba)
Tedizolid Phosphate (Sivextro)
Oritavancin (Orbactiv/ Nuvocid)
Ceftolozane-Tazobactam (Zerbaxa)
Ceftazidime-Avibactam (Avycaz/ Zavicefta)
PHASE III DRUGS

Segment by Indication
Complicated Urinary Tract Infection (CUTI)
Complicated Intra-Abdominal Infections (CIAI)
Blood Stream Infections (BSI)
Clostridium Difficile Infections (CDI)
Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Melinta Therapeutics
Allergan
Merck
Abbott Laboratories
Pfizer
GSK
PENDOPHARM
Absynth Biologics
Achaogen
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
Demuris
Evolva Holding
ContraFect
Cerexa
InterMune
Isis Pharmaceuticals
Lyndra
Microbecide
Morphochem
Nabriva Therapeutics
NanoSafe Coatings
Novexel
Osel
VenatoRx Pharmaceuticals
AAIPharma Services
ANTABIO